Increased bone marrow toxicity of doxorubicin bound to nanoparticles

Area of Science:

• Pharmacology
• Nanomedicine
• Oncology

Background:

• Doxorubicin is a widely used chemotherapy agent with significant myelosuppressive side effects.
• Nanoparticle drug delivery systems aim to improve drug efficacy and reduce toxicity.
• Polyalkylcyanoacrylate nanoparticles are being investigated for their potential in drug delivery.

Purpose of the Study:

• To compare the in vivo myelosuppressive effects of free doxorubicin versus doxorubicin bound to polyisobutyl (doxo-PIBCA) and polyisohexylcyanoacrylate (doxo-PIHCA) nanoparticles.
• To evaluate the correlation between drug concentration in bone marrow and spleen with myelosuppression.
• To investigate the role of colony stimulating factors in the myelosuppressive effects of these formulations.

Main Methods:

• In vivo mouse model for assessing myelosuppression.
• Intravenous administration of free and nanoparticle-bound doxorubicin (11 mg/kg).
• Analysis of blood, bone marrow, and spleen cell counts; CFU-GM progenitor assays; HPLC for drug concentration.
• Measurement of colony stimulating factors.

Main Results:

• Doxo-PIHCA nanoparticles exhibited the most pronounced and sustained myelosuppressive effects.
• High doxorubicin concentrations were found in the bone marrow and spleen with doxo-PIHCA.
• PIHCA nanoparticles induced colony stimulating factor release, potentially exacerbating doxorubicin's toxicity to bone marrow progenitors.

Conclusions:

• Polyisohexylcyanoacrylate-bound doxorubicin demonstrates significant and prolonged myelosuppression in vivo.
• The enhanced myelosuppression is linked to high drug concentrations in hematopoietic tissues and induced release of colony stimulating factors.
• Further studies focusing on bone marrow progenitors are crucial for evaluating targeted anticancer drug formulations.